NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.5210
-0.0175 (-3.25%)
At close: 3:59PM EDT

0.5390 +0.01 (2.84%)
After hours: 6:04PM EDT

Stock chart is not supported by your current browser
Previous Close0.5385
Open0.5380
Bid0.5200 x 1200
Ask0.5390 x 1000
Day's Range0.5210 - 0.5400
52 Week Range0.3700 - 5.0000
Volume993,062
Avg. Volume3,059,912
Market Cap38.736M
Beta (3Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga7 days ago

    Penny Stock Neovasc Rallies On Patent Abstract Filing

    Shares of the Canadian medical device maker Neovasc Inc (NASDAQ: NVCN) were rallying Tuesday following the circulation of a document with a patent abstract it filed with the U.S. Patent and Trademark Office. The patent abstract pertains to the methods and apparatus for loading a prosthesis onto a delivery system. This relates to the company's Tiara prosthetic valve, which replaces the mitral valve of the heart when delivered through the apex of the heart.

  • Benzinga25 days ago

    A Look At Benzinga Pro's Most-Searched Tickers For May 24

    Tesla Inc  (NASDAQ: TSLA ) shares dropped 2.5 percent to $190.52. The stock rebounded above $200 on Thursday on news of a purported internal email from Musk on the company's fourth-quarter deliveries. ...

  • Benzinga26 days ago

    The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Axsome Therapeutics Inc (NASDAQ: AXSM ) Milestone Pharmaceuticals ...

  • Associated Presslast month

    Neovasc: 1Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had a loss of 21 cents per share. Losses, adjusted for asset impairment costs, came to 20 cents per share. The medical device company posted revenue ...

  • Associated Press3 months ago

    Neovasc: 4Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had profit of 51 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The medical device company posted revenue of $523,400 ...

  • Benzinga3 months ago

    The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...

  • Associated Press7 months ago

    Neovasc: 3Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had a loss of 70 cents per share. Losses, adjusted for amortization costs and non-recurring costs, were 61 cents per share. The medical device company ...

  • Benzinga7 months ago

    Neovasc Q3 Earnings Preview

    Neovasc Inc. - Common Shares (NASDAQ: NVCN ) announces its next round of earnings this Wednesday, Nov. 14. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement. Earnings and ...

  • Benzinga8 months ago

    Neovasc Broadcasts Surgery With Mitral Valve Device Live At Medical Conference

    Neovasc said its Tiara transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 32nd Annual European Association for Cardio-Thoracic Surgery Meeting held in Milan, Italy. Tiara is being developed by Neovasc for treating mitral regurgitation, a condition affecting about 4 million patients in the U.S.

  • Why Neovasc Stock (NVCN) Is Skyrocketing Today
    InvestorPlace8 months ago

    Why Neovasc Stock (NVCN) Is Skyrocketing Today

    Neovasc stock (NASDAQ:NVCN) is skyrocketing more than 26% on Wednesday as the company received good news from the U.S. Food and Drug Administration (FDA) regarding one of its latest products. The medical device company revealed that its Neovasc Reducer device that was designed to treat refractory angina was granted a Breakthrough Device designation by the FDA. The news caused Neovasc stock to skyrocket with volume soaring up to 21.2 million shares, which is considerably higher than the stock’s full-day average of just under 800,000 shares.

  • Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session
    Zacks9 months ago

    Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session

    Neovasc (NVCN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Associated Press10 months ago

    Neovasc: 2Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had a loss of 4 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, were less than 1 cent on a per-share basis. The ...

  • What Does Neovasc Inc’s (TSE:NVCN) Ownership Structure Look Like?
    Simply Wall St.10 months ago

    What Does Neovasc Inc’s (TSE:NVCN) Ownership Structure Look Like?

    In this article, I’m going to take a look at Neovasc Inc’s (TSE:NVCN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • Investopedialast year

    Should You Snap up Medical Device Stock Neovasc Now?

    Neovasc Inc (NASDAQ: NVCN), a specialty medical device company that develops, manufactures and markets products for the cardiovascular segment of the healthcare market is witnessing great traction this week. The company has just announced its first patient implant using its flagship medical device, NVCN reducer. Here we use TipRanks data to take a closer look at what Wall Street’s top analysts see in store for this volatile stock.